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ABSTRACT  
Concurrent use of cocaine and heroin is a major public health issue, with no effective relapse 
prevention treatment currently available. To this purpose, a combination of buprenorphine and 
naltrexone, a mixed very-low efficacy mu-opioid receptor agonist / kappa-opioid receptor 
antagonist / NOP receptor agonist, was investigated. The tail withdrawal and the conditioned 
place preference assays in adult Sprague Dawley rats were used to show that naltrexone dose-
dependently blocked the mu-opioid receptor agonism of buprenorphine. Furthermore, in the 
conditioned place preference assay, a combination of 0.3 mg/kg buprenorphine and 3.0 mg/kg 
naltrexone was aversive. A combination of 0.3 mg/kg buprenorphine and 1.0 mg/kg naltrexone 
was neither rewarding nor aversive, but still possessed mu-opioid receptor antagonist properties. 
In the conditioned place preference extinction and reinstatement method, a combination of 0.3 
mg/kg buprenorphine and 1.0 mg/kg naltrexone completely blocked drug-primed reinstatement in 
cocaine-conditioned rats (conditioned with 3 mg/kg cocaine, drug prime was 3 mg/kg cocaine), 
and attenuated drug-primed reinstatement in morphine-conditioned rats (conditioned with 5 mg/kg 
morphine, drug prime was 1.25 mg/kg morphine). These data add to the growing evidence that a 
buprenorphine/naltrexone combination may be protective against relapse in a polydrug abuse 
situation.  
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INTRODUCTION 
 
There is currently no medication licensed in Europe or the US for treatment of cocaine 
dependence, and whilst there are treatments available for opioid dependence, no single treatment 
is effective for everyone. As many users of crack cocaine are also dependent on heroin, a relapse 
prevention medication that is effective in the polydrug user population would be a notable step 
forward.   
 
In this paper, the ability of a combination of buprenorphine and naltrexone to inhibit reinstatement 
of morphine and cocaine conditioned place preference was investigated. Buprenorphine is a partial 
agonist at the mu-opioid receptor, an antagonist at the kappa-opioid receptor and a partial agonist 
at the nociceptin (NOP) receptor (Huang et al. 2001). Buprenorphine, like methadone, is widely 
used as a substitution therapy for treatment of opioid addicts (Maremmani and Gerra 2010), but 
clinical studies have shown that buprenorphine, but not methadone, is also effective in reducing 
cocaine use (Kosten, Kleber & Morgan 1989). Naltrexone is an antagonist at both mu- and kappa-
opioid receptors (Giordano, Nock & Cicero 1990) and has been shown to reduce both opioid 
(Comer et al. 2006) and cocaine use (Schmitz et al. 2001).  
 
Encouraging results have been observed in two clinical trials using a buprenorphine/naltrexone 
combination therapy (Rothman et al. 2000; Gerra, Fantoma & Zaimovic 2006); significant 
reduction of both heroin and cocaine use was demonstrated. Currently, buprenorphine is licensed 
as an opioid substitution therapy, but is in itself rewarding via activation of the mu-opioid receptor 
(Greenwald et al. 2007). Combination of buprenorphine with sufficient naltrexone can block 
buprenorphine’s mu-opioid receptor agonism (Dum and Herz 1981; McAleer et al. 2003) thus 
increasing regulatory acceptability, and feasibility of its use in cocaine addicts. Naltrexone is itself 
licensed as an abstinence-promoter but treatment success is hindered by low compliance. 
Naltrexone provides no reinforcement or pleasure, but, as a mu-opioid receptor antagonist, is 
likely to block rewards caused by release of endogenous opioid peptides (Kirchmayer et al. 2002; 
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Mucha, Millan & Herz 1985). Indeed, in laboratory animals, naltrexone alone has been shown to 
be aversive at high doses (Parker and Rennie 1992, Suzuki et al. 1992).  
 
Thus, the combination of buprenorphine and naltrexone may be neither rewarding nor aversive, 
but still an effective anti-addiction therapy. In addition to effects on mu-opioid receptors, the 
buprenorphine/naltrexone combination acts as an antagonist at the kappa-opioid receptor. 
Comorbid affective disorders can emerge on cessation of use of drugs of abuse (Gerra et al. 
2006), and antagonism of the kappa-opioid receptor appears to counter depression in rodents 
(Mague et al. 2003; Beardsley et al. 2005). Further, the kappa-opioid system and its endogenous 
agonist dynorphin have been shown to mediate many stress responses; in preclinical studies, 
inhibition or genetic ablation of kappa-opioid receptors has been shown to inhibit stress-induced, 
but not drug-prime-induced, reinstatement to cocaine-seeking behavior (reviewed by Bruchas, 
Land & Chavkin 2010). 
 
Another component of the pharmacology of a buprenorphine/naltrexone combination is to act as a 
partial agonist at the NOP receptor. Selective NOP agonists are neither rewarding nor aversive 
(Le Pen et al. 2002) and, although the mechanism is poorly understood, they have been shown in 
rodents to oppose the effects of cocaine and morphine (Kotlinska et al. 2002; Sakoori and Murphy 
2004), inhibiting drug-primed reinstatement of morphine conditioned place preference (CPP) 
(Shoblock, Wichmann & Maidment 2005). The effect of NOP agonists on reinstatement of cocaine 
CPP has not been studied to date. 
 
Overall, a mixed very-low efficacy mu-opioid receptor agonist / kappa-opioid receptor antagonist / 
NOP receptor agonist is a desirable target as a novel anti-addiction therapy (McCann 2008). The 
reduction in cocaine use observed in the studies carried out by Rothman and Gerra could be via 
antagonism of mu-opioid receptors attenuating the positive reinforcing effects of cocaine (Bilsky et 
al. 1992), via antagonism of kappa-opioid receptors conferring stress resilience (Redila and 
Chavkin 2008), or via more generalized anti-addictive effects of agonism of the NOP receptor 
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(Shoblock et al. 2005; Kuzmin et al. 2007). Alternatively, it could simply be a consequence of 
reduction in heroin use (these two drugs of abuse are often used by addicts to ‘complement’ each 
other). Therefore, the effect of buprenorphine/naltrexone on the effects of cocaine in a controlled 
experiment has been assessed here. The aims of this study were to determine the ratio of 
buprenorphine/naltrexone that is neither rewarding nor aversive, and then to evaluate how this 
drug combination can inhibit drug-primed reinstatement of both morphine- and cocaine-induced 
conditioned place preference. 
 
 6
MATERIALS AND METHODS 
 
Subjects 
All experiments were performed in accordance with the U.K. Animals (Scientific Procedures) Act of 
1986 and the University of Bath’s ethical review documents. Male Sprague Dawley rats (Charles 
River, UK) were used; 260-420g (7-11 weeks old) for tail withdrawal and rat vas deferens 
experiments, 250-320g (7-9 weeks old) for conditioned place preference experiments. All rats were 
housed four per cage with ad libitum access to food and water and maintained on a 12:12 h light-
dark cycle (lights on 07:00, lights off 19:00).   
 
Tail withdrawal assay 
A water bath (Grant Instruments, UK) was maintained at 52ºC. The rats were held firmly in a 
vertical position, and lowered until the distal third of the tail was in the water. The time taken for 
the rat to withdraw the tail was recorded. A 20 second cut-off was imposed to avoid tissue 
damage. All rats were opioid naïve, and were not reused. 
 
Measurement of receptor affinity – rat vas deferens 
Rats were killed using CO2 and vasa deferentia were excised and suspended in a siliconized 
tissue bath (3 ml volume) under 0.5 g tension in Krebs-bicarbonate solution (composition (mM): 
NaCl 118, KCl 4.74, CaCl2 2.50, KH2PO4 1.19, MgSO4 1.20, NaHCO3 25, glucose 11, bubbled 
with 95% O2 / 5% CO2, maintained at 37oC). Nerve-evoked muscle contractions were induced with 
single square pulses (0.1 ms duration, 0.1 Hz, supramaximal voltage) and measured isometrically 
with ‘LabChart’ software (AD Instruments). Cumulative concentration response curves to the 
selective mu-opioid receptor agonist, [D-Ala2,NMe-Phe4,Gly-ol5]-enkephalin (DAMGO; 
concentration increased at 5-minute intervals) were constructed in the absence then presence of 
buprenorphine or naltrexone.  
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In individual tissues, EC50 values for DAMGO in the absence and presence of buprenorphine or 
naltrexone were derived by fitting data to a non-linear regression curve-fit (GraphPad Prism) using 
the equation:  
Effect = baseline + (Emax-baseline)/(1+10^((LogEC50 - X)*HillSlope)) 
where X is the agonist concentration. 
 
For naltrexone, a Schild plot was constructed, deriving a pA2 value (equivalent to the log KB 
value). As buprenorphine has been shown to be pseudo-irreversible, KB values were obtained 
using a single concentration of buprenorphine (1 nM) and the Schild equation. 
 
Calculations of relative receptor occupancy were derived using the following equation:  
% occupancy of drug A = 100 * ([A]/KA) / (([A]/KA) + ([B]/KB) + 1)  
 
Blood and brain tissue concentrations 
Plasma sample preparation - Blood samples (30-minute post-injection) were centrifuged (3300 rpm, 10 
minutes), and plasma recovered. Plasma samples were basified using ammonium hydroxide solution 
(pH 10) and loaded onto a solid phase extraction (SPE) cartridge (Waters Oasis HLB) previously 
conditioned with 1 ml methanol and 1 ml water. The cartridge was washed with 1 ml 2% methanol in 
ammonium hydroxide solution (pH 10), rinsed with water, then the analyte was eluted with 440 µl 60% 
methanol containing 2% acetic acid. The sample was filtered (nylon 0.45 µm syringe filter) before 
injection into the LC-MS. Samples were injected undiluted to analyse buprenorphine, then diluted 1:1 
with water to analyse naltrexone. 
 
Brain tissue sample preparation - The brain tissue (30-minute post-injection) was prepared using the 
same SPE process as the plasma samples. Prior to the SPE process water was added (1.8 ml/gram of 
brain tissue) to facilitate homogenisation (Tissue Master 240, OMNI International, US), the sample was 
centrifuged, and the supernatant fluid was collected. 
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Buprenorphine and norbuprenorphine LC-MS method - Separation was performed using a GeminiNX 
column (3µm C18 110A 50 x 2mm) from Phenomenex, maintained at 25°C, on a Shimadzu LC-
2010AHT HPLC. The mobile phase was 18:82 acetonitrile: 0.1% acetic acid at a flow rate of 
0.2 ml/min. 30µl of sample was injected. 
 
The retention times for buprenorphine and norbuprenorphine were 9 and 3 minutes; masses per 
charge were 468 and 414. Standards were prepared in SPE eluent. Limit of quantitation was 0.18 
ng/ml for buprenorphine and 0.8 ng/ml for norbuprenorphine. 
 
Naltrexone and 6ß-naltrexol LC-MS method - The method for analysis of naltrexone and 6ß-naltrexol 
was adapted from Valiveti (2004). Separation was performed using a Symmetry column (5µm C18 
110A 150 x 2.1 mm) from Waters, maintained at 23°C, on a Shimadzu LC-2010AHT HPLC. The 
mobile phase was 12:88 acetonitrile: 0.1 % ammonium acetate at a flow rate of 0.25 ml/min. 30µl of 
sample was injected.  
 
The retention times for naltrexone and 6ß-naltrexol were 4 and 3 minutes; masses per charge were 
342 and 344. Standards were prepared in SPE eluent. Limit of quantitation was 3.8 ng/ml for 
naltrexone and 0.28 ng/ml for 6ß-naltrexol.  
 
Conditioned place preference apparatus 
CPP boxes (Tracksys, UK) were three-chambered shuttle boxes comprising a small central 
compartment (10 x 10 cm) where rats were placed at the start of a test session, and two larger 
compartments (40 x 40 cm), one with horizontal black and white stripes, and one with vertical 
black and white stripes. Floors were made of stainless steel sheeting with punched-out shapes 
(circles, 12 mm hole, and squares, 10 mm hole) resulting in distinct textures (Novametals, UK). 
Removable partitions allowed the boxes to be used either to restrict the rats to a particular 
compartment for conditioning, or to allow the rats to be ‘free-to-explore’ during a test session. 
Experiments were performed between 8 am and 5 pm under dim white light (light intensity approx. 
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15 lux). During all test sessions, the time each rat spent in each compartment was recorded using 
EthoVision XT (Tracksys, UK) tracking software. 
Rats were assigned to treatment groups randomly, and the pairing was counterbalanced (i.e., 
within each cohort, equal numbers of rats were always drug-paired to each compartment type). 
Groups were organised such that mean baseline % preferences were close to zero. 
CPP. Data throughout are presented after multiplying by a correction factor. The correction factor 
was calculated by dividing duration of test (seconds) by total time spent (seconds) in the two large 
compartments. This factor is used to proportionally divide the time spent in the neutral central 
compartment between the two conditioning compartments.  
 
% preference was calculated using the corrected data such that if a rat spent equal time in the 
drug-paired compartment and the saline-paired compartment, the preference score would be zero 
%. If a rat spent no time in the saline-paired compartment, the preference score would be 100 %.  
 
Individual rats whose baseline preference was >16.7 or <-16.7 were excluded. 
 
Drugs and chemicals 
Naltrexone hydrochloride dihydrate was from Fluka (UK). Saline (sodium chloride 0.9%) was from 
Dechra (UK). Buprenorphine hydrochloride was prepared in-house. Cocaine hydrochloride and 
morphine sulphate were from MacFarlan Smith (UK). All in vivo injections were intraperitoneal (1 
ml/kg).  
DAMGO was from Bachem (UK). Sigmacote®, buffer components and mobile phase components 
were from Sigma (UK). 
 
PROCEDURES 
 
Using naltrexone to block the rewarding effects of buprenorphine 
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Two separate assays, tail withdrawal and CPP, were used to establish the dose of naltrexone 
required to block the mu-opioid receptor agonism of buprenorphine.  
 
Tail withdrawal assay. Five baseline measurements were taken, one immediately after another, 
for each rat. 0.3 mg/kg buprenorphine was then administered in combination with either 0, 0.3 or 
1.0 mg/kg naltrexone (n = 5, 4, 7). Following injection of the drug, measurements were taken once 
every 7.5 minutes, up to 60 minutes. Data collected at the 60 minute time-point was used in 
subsequent analyses. Baseline tail-withdrawal time was taken as the mean of the last 2 baseline 
measurements. For each rat, analgesia was quantified as tail-withdrawal time post-drug treatment 
minus baseline measurement. Data were analysed using one-way ANOVA with the Bonferroni 
post-test. 
 
CPP assay. Rats were conditioned with buprenorphine (0.3 mg/kg) administered in combination 
with either 0, 0.3, 1 or 3 mg/kg naltrexone (n = 16, 8, 8, 16). On day 1, rats had a 15 minute 
exploratory session; on day 4, they had a 15 minute baseline preference test. A % preference was 
obtained. On days 5-8 and 11-14, the rats received drug or saline on alternate days, thus, each rat 
had 4 drug injections and 4 saline injections. Injections were administered at least 24 hours apart 
to ensure that the effects of buprenorphine had dissipated before subsequent saline injections. 
Following injections, the rats were immediately confined to a compartment for 40 minutes. On day 
15, % preference was obtained exactly as for baseline preference; i.e., the preference for each 
drug treatment was measured by recording the time spent in the drug-paired chamber in a free-to-
explore test lasting 15 minutes. To assess conditioning, a 1-tailed Wilcoxon matched pairs signed-
rank test was used (each group’s % preference after drug treatment compared to its baseline).  
 
Measuring mu-opioid receptor antagonism of a buprenorphine/naltrexone combination 
Five baseline measurements were taken. Latency to withdrawal was measured following 
administration of 10 mg/kg morphine only (n = 4), and when both 0.3 mg/kg buprenorphine and 
1.0 mg/kg naltrexone (n = 5) or 1.0 mg/kg naltrexone alone (n = 7) were administered 30 minutes 
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prior to the morphine. Following injection of the morphine, measurements were taken once every 
5 minutes, up to 30 minutes. Data collected at the 30 minute time point was used in subsequent 
analyses. 
 
Effects of buprenorphine/naltrexone on reinstatement of cocaine and morphine 
conditioned place preference 
To test the ability of a buprenorphine/naltrexone combination to block drug-primed reinstatement, 
a conditioned place preference extinction and reinstatement method was established (Figure 1).  
 
Rats had one 15 minute exploratory session and one 15 minute baseline preference test. Animals 
were conditioned using either 3 mg/kg cocaine or 5 mg/kg morphine, receiving drug and saline on 
the same day (at least 4 hours apart) for 3 consecutive days. Immediately after injection, rats were 
confined to a particular compartment (drug-paired or saline-paired) in the CPP box (for 20 minutes 
or 40 minutes, cocaine and morphine respectively). Following conditioning, % preference was 
obtained exactly as for baseline preference. Individual rats which showed less than a 30-second 
increase for drug-paired side over their baseline preference during the post-conditioning test were 
excluded from extinction and reinstatement. To assess conditioning before exclusions, a 1-tailed 
Wilcoxon matched pairs signed-rank test was used (each group’s % preference after drug 
treatment compared to its baseline). 
 
Four cohorts of rats were used: cocaine-conditioned control (n = 20), morphine-conditioned 
control (n = 24), cocaine-conditioned buprenorphine/naltrexone treatment (n = 16), and morphine-
conditioned buprenorphine/naltrexone treatment (n = 16). 
 
For all cocaine-conditioned rats, extinction was achieved by reconditioning. This involved injection 
of saline followed by confinement to a compartment for 20 minutes, twice a day for 4 days (4 
hours apart). The rats were alternated daily as to whether they were placed in the previously drug-
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paired compartment or the previously saline-paired compartment morning or afternoon. Extinction 
was confirmed by a 15 minute free-to-explore test (day 15, see Figure 1).  
 
For the morphine-conditioned rats, two styles of extinction were used: a reconditioning style of 
extinction (saline injection with 15 minutes confinement in each compartment, as above), and a 
retesting style of extinction (daily retesting, 15 minutes per test). Of the animals subsequently 
tested for reinstatement, 5 rats in the control group underwent extinction training using the 
reconditioning style, and 9 underwent extinction using the retesting style. All rats in the 
buprenorphine/naltrexone treatment group underwent extinction training using the reconditioning 
style.  
 
Extinction training was deemed complete if group mean preference was <5%. For the retesting 
style of extinction, this was taken from the average of 2 consecutive days. Following extinction, 
rats were administered a priming dose of 3 mg/kg cocaine or 1.25 mg/kg morphine. The control 
groups received a saline injection 10 minutes prior to drug priming and the treatment groups 
received a buprenorphine/naltrexone injection (0.3 and 1 mg/kg respectively) 10 minutes prior to 
drug priming. Following administration of the priming dose, rats were placed immediately into the 
CPP boxes and were free-to-explore during a 30-minute test.  
 
Conditioning and reinstatement were assessed using the Friedman test followed by Dunn's 
multiple comparison test (each group’s % preference compared to its baseline). A Mann-Whitney 
U test was used to compare the % preference during the reinstatement test for rats that had 
undergone a retesting style of extinction and for rats that had undergone a reconditioning style of 
extinction.  
It was observed that in the control groups, conditioned place preference behavior emerged at 13-
15 minutes of the reinstatement test period in cocaine-conditioned rats; however, in the morphine-
conditioned rats, drug-seeking was evident from the start of the reinstatement test period and then 
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diminished somewhat after 15 minutes (data not shown). The data from 0-30 minutes of the 
reinstatement test were used for the cocaine-conditioned rats, whereas, the data from 0-15 
minutes of the test were used for the morphine-conditioned rats. It is interesting that these findings 
are in contrast to Mueller and Stewart (2000) and Mueller, Perdikaris & Stewart (2002) who 
observed gradual emergence of drug-seeking over the course of the reinstatement test in both 
cocaine- and morphine-conditioned rats. 
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RESULTS 
Using naltrexone to block the rewarding effects of buprenorphine 
Tail withdrawal assay. Tail withdrawal is a commonly used assay of analgesia, and was used here 
as an indirect measure of mu-opioid receptor agonism. A dose of 0.3 mg/kg buprenorphine was 
selected because previous studies in rats have indicated that this dose is rewarding in the CPP 
assay (Suzuki et al. 1992; Rowlett, Gibson & Bardo 1994; Tzschentke 2004), and can elicit 
measureable mu opioid receptor-mediated analgesia (Lutfy et al. 2003). Figure 2 (panel A) shows 
that 0.3 mg/kg buprenorphine elicited marked analgesia in this experimental set-up. This can be 
seen by the increase in time taken to withdraw the tail compared to baseline. A clear dose-
dependent effect of naltrexone countering buprenorphine-induced analgesia was observed. 
 
CPP assay of rewarding effects of buprenorphine. Group mean baseline preferences were 0 ± 2, 
2 ± 5, 2 ± 2 and 0 ± 2 % (mean ± SEM). One rat in the 0.3 mg/kg buprenorphine group and one 
rat in the 0.3 mg/kg buprenorphine and 0.3 mg/kg naltrexone group were excluded for having a 
preference at baseline. 
 
0.3 mg/kg buprenorphine elicited drug-seeking behavior in this set-up (Figure 2, panel B). This 
can be seen as a significant increase in time spent in the drug-paired compartment compared to 
baseline. As observed in the tail withdrawal assay, a clear dose-dependent effect of naltrexone 
was observed; naltrexone countered the rewarding effects of buprenorphine to the extent that co-
administration of 3.0 mg/kg naltrexone actually elicited aversion (rats spent significantly more time 
in the saline–paired compartment compared to baseline test). 
 
There was good agreement between the results of the tail withdrawal and the CPP assays; taken 
together, it was clear that, in these rats, 1.0 mg/kg naltrexone blocked the mu-opioid receptor 
agonism of 0.3 mg/kg buprenorphine. This finding fits with earlier data (Walker et al. 1994) which 
showed that 1.0 mg/kg naltrexone blocked the subjective effects of 0.3 mg/kg buprenorphine in a 
discrimination assay in rats. A combination of 0.3 mg/kg buprenorphine and 1.0 mg/kg naltrexone 
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was therefore selected for use in subsequent behavioral experiments.  
 
Measuring mu-opioid receptor antagonism of a buprenorphine/naltrexone combination 
After establishing that 1.0 mg/kg naltrexone was sufficient to block the mu-opioid receptor 
agonism of 0.3 mg/kg buprenorphine, we tested whether this combination would show mu-opioid 
receptor antagonism. 10 mg/kg morphine elicited a measurable analgesia (Figure 3).  
 
Clear mu-opioid receptor antagonism was observed following administration of 
buprenorphine/naltrexone (morphine-induced analgesia decreased from 16 ± 0 to 3 ± 1 seconds, 
mean ± SEM). Administration of naltrexone alone blocked morphine-induced analgesia to a 
greater extent than did the combination.  
 
CPP extinction and reinstatement model 
The CPP extinction and reinstatement method is frequently used to study the effects of potential 
relapse prevention treatments (reviewed by Aguilar, Rodriguez-Arias & Minarro 2009).  This 
method was therefore used to observe drug-primed reinstatement in cocaine- and morphine-
conditioned rats, and the effects thereon of pre-treatment with a buprenorphine/naltrexone 
combination. Table 1 shows the number of rats used in the experiments, the number of rats 
excluded, and the time taken to reach extinction. Conditioning was statistically significant in each 
cohort before individual rats were excluded for insufficient conditioning. 
 
 
Control groups. Figure 4 shows the data for the control groups (panels A and B). The % 
preference post-conditioning and following a drug prime was significantly different from baseline 
for both drugs. In other words, reinstatement of drug-seeking was successfully attained in both 
control groups. As there was no significant difference in % preference during the reinstatement 
test between the morphine-conditioned rats, which underwent the two styles of extinction training 
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used (reconditioning 11 ± 7 % n = 5, retesting 19 ± 9 % n = 9, mean ± SEM), pooled data are 
shown.  
 
Buprenorphine/naltrexone treatment groups. Figure 4 shows the data for the buprenorphine 
/naltrexone treated groups (panels C and D); the effect of the combination on drug-primed 
reinstatement in cocaine- and morphine-conditioned rats is clear. Preference during reinstatement 
test was not significantly different from baseline for either drug. In the cocaine-conditioned rats, 
the buprenorphine/naltrexone treatment completely blocked reinstatement (preference score of -9 
± 5 % mean ± SEM compared to 11 ± 5 in the control group). In the morphine-conditioned rats, 
the buprenorphine/naltrexone treatment attenuated the preference observed following 
administration of a drug prime (preference score of 6 ± 10 %, mean ± SEM compared to 16 ± 6 in 
the control group).  
 
Receptor occupancy of buprenorphine and naltrexone 
Having demonstrated that a combination of 0.3 mg/kg buprenorphine and 1.0 mg/kg naltrexone is 
neither rewarding nor aversive, and is capable of blocking drug-primed reinstatement to cocaine- 
and morphine-seeking, we next estimated the relative receptor occupancies of both drugs. 
 
Receptor affinity values were determined in isolated tissue (rat vas deferens) and logKB values 
were -9.38±0.12 for buprenorphine (ie. KB = 0.41 nM) and -8.90±0.12 for naltrexone (ie. KB = 1.26 
nM) (Figure 5). Plasma and brain concentrations were measured 30 minutes after administration 
of buprenorphine (0.3 mg/kg) and naltrexone (1.0 mg/kg) (Table 2). From these data, receptor 
occupancy levels of each could be estimated.  
 
These data suggest that >95% of all available mu-opioid receptors are occupied either by 
buprenorphine or naltrexone when administered at these doses, which, as Figure 3 shows, is 
sufficient to block morphine-induced analgesia. Furthermore, when buprenorphine (0.3 mg/kg) is 
co-applied with naltrexone (1.0 mg/kg), buprenorphine only occupies ~40% of available receptors, 
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and at this receptor occupancy level there is not sufficient mu-opioid receptor activation to 
produce either analgesic or rewarding effects (see Figure 2). In addition, similar experiments (data 
not shown) were performed to determine the affinity of buprenorphine at kappa-opioid receptors. 
The KB value of buprenorphine at kappa-opioid receptors (0.6 nM) means that at the observed 
brain concentrations, >95% of all available kappa-opioid receptors would be occupied by 
buprenorphine or naltrexone. 
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DISCUSSION 
Data from both the tail withdrawal and the conditioned place preference assays showed that 0.3 
mg/kg buprenorphine alone displayed marked mu-opioid receptor agonism and that naltrexone 
dose-dependently blocked the mu-opioid receptor agonism in both assays. A critical feature for a 
potential anti-addiction therapy is that the therapy itself is neither rewarding (and therefore would 
itself have an abuse liability) nor aversive (and could reduce compliance or effectiveness 
(Greenwald et al. 2007; Manlandro 2007; Nutt 2010)). In our study, although 0.3 mg/kg 
buprenorphine alone was rewarding, as seen by conditioned place preference, when 
buprenorphine was administered in combination with 1.0 mg/kg naltrexone the combination was 
neither rewarding nor aversive. If a higher dose of naltrexone (3.0 mg/kg) was used, the 
combination became aversive. Previous studies have shown that mu-opioid receptor antagonism 
can induce conditioned place aversion, an effect attributed to blockade of endogenous opioid 
activity (Mucha et al. 1985).  
 
We generated estimates of relative receptor occupancies following buprenorphine/naltrexone 
combination (0.3 / 1 mg/kg). >95% of available mu-opioid receptors were estimated to be 
occupied, 40% of these by buprenorphine. One caveat is that we could only measure absolute 
brain levels rather than free concentrations of each drug. A high proportion of the compounds may 
be in the lipid compartment and unavailable for receptor binding (buprenorphine being particularly 
lipophilic). In vivo autoradiography studies have found in vivo KD values for buprenorphine and 
naltrexone at mu-opioid receptors to be approximately 23 and 30 g/kg respectively (Richards and 
Sadée 1985; Höllt et al. 1975). Although brain and plasma concentrations were not measured in 
those studies, if we extrapolate from our empirical brain concentrations, this suggests brain 
concentrations for both drugs in those studies would be approximately 10x higher than in vitro KB 
values. Hence, approximately 10% of both buprenorphine and naltrexone in the brain would be 
‘free’. If this were the case, this would have a negligible impact on both relative and total receptor 
occupancy by buprenorphine and naltrexone at the doses used in this study, based on the fact that 
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the doses used here resulted in brain levels of both drugs far in excess (>100-fold higher) of their 
KB values.  
 
The clinical trials carried out by Rothman et al. (2000) and Gerra et al. (2006) administered 
naltrexone orally (50mg daily) and buprenorphine sublingually (4mg daily). Although plasma drug 
concentrations were not performed in those studies, they would likely have been of the order of 
4nM buprenorphine and 60nM naltrexone (peak levels) declining to 0.4nM buprenorphine and 3nM 
naltrexone (at 24 hours) (Everhart et al. 1997; Verebey et al. 1976), compared to 56nM 
buprenorphine and 285nM naltrexone in this study. While there are limits to the extent to which our 
studies in rat can be compared to clinical studies, our data suggest two things for future clinical 
studies. Firstly, that the ideal buprenorphine:naltrexone plasma concentration ratio is around 1:5, 
theoretically meaning that relatively higher buprenorphine doses would be more clinically effective. 
Secondly, higher doses of both buprenorphine and naltrexone than those used by Rothman et al. 
(2000) and Gerra et al. (2006) may be even more effective clinically, as the combination would 
result in greater mu and kappa-opioid receptor occupancies.  
 
The ratio of naltrexone to buprenorphine dose in the current study (3:1) is very different to that 
used in a recent study examining cocaine self-administration in rats (Wee et al. 2012) where 0.3 
mg/kg naltrexone and 3 mg/kg buprenorphine was predominantly used (1:10). Although different 
routes of administration were used (subcutaneous in Wee et al. 2012; intraperitoneal in the current 
study), our data would suggest that if more buprenorphine than naltrexone is administered, there 
would still be a significant mu-opioid receptor agonist response. Indeed, Wee et al. (2012) showed 
that although 0.3 mg/kg naltrexone reduced somatic withdrawal signs and analgesia following 3 
mg/kg buprenorphine, there were still significant signs of residual mu-opioid receptor activation. 
Our study shows that when plasma and brain levels of buprenorphine are around 4-5-fold less than 
that of naltrexone there is no measurable mu-opioid receptor agonist response.  
 
The reduction in morphine-induced analgesia in the tail withdrawal test following administration of 
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the combination indicates that the combination has significant mu-opioid receptor antagonist 
properties. Indeed, when buprenorphine and naltrexone were administered in combination, >95% 
of available mu-opioid receptors were estimated to be occupied. However, the combination did not 
counter morphine to the same extent as naltrexone alone. This may be because of very low levels 
of mu-opioid receptor activation by the buprenorphine/naltrexone combination which, although 
below the level of functional effect, may be added to with a morphine challenge.  
 
Data generated using the CPP extinction and reinstatement method showed clearly that 
buprenorphine/naltrexone reduced reinstatement to drug-seeking following a drug prime, in both 
cocaine- and morphine-conditioned rats. Unexpectedly, the effect was more dramatic in the 
cocaine-conditioned rats. Whilst there is preclinical data showing that buprenorphine (Kosten, 
Marby & Nestler 1991; Suzuki et al. 1992; Comer et al. 1993) and naltrexone (Bilsky et al. 1992; 
Suzuki et al. 1992) can reduce the ability to acquire a conditioned place preference to cocaine, the 
research here goes further. Firstly, the ability of buprenorphine and naltrexone to block 
reinstatement to cocaine-seeking following extinction was demonstrated, and secondly, the two 
compounds were administered as a combination that by itself induces neither conditioned place 
preference nor aversion. Importantly, the observed reduction in cocaine-seeking implies that the 
decrease in cocaine use reported in clinical trials (Rothman et al. 2000; Gerra et al. 2006) was 
probably not a simple consequence of reduced heroin use.  
 
As well as blocking mu-opioid receptors, the combination of buprenorphine and naltrexone used 
here also acts as a functional kappa-opioid receptor antagonist (>95% estimated occupancy of 
available kappa-opioid receptors). However, kappa-opioid receptor antagonism is not thought to 
be effective in blocking drug-primed reinstatement to cocaine (Beardsley et al. 2005), only in 
blocking that which is stress-induced (Beardsley et al. 2005; Carey et al. 2007; Land et al. 2009). 
Therefore, it may be postulated that the successful blocking of reinstatement to cocaine-seeking 
observed here was due, at least in part, to some ‘non-kappa’ effects, such as mu-opioid receptor 
antagonism. Certainly, the opioid system is heavily involved in the hedonic response and the 
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subsequent reinforcement process of all drugs of abuse, including cocaine (Kalivas and Tang, 
2005; Soderman & Unterwald 2008; Le Merrer et al. 2009). Whilst NOP activation in mice has 
been shown to counteract cocaine reward (Bebawy et al. 2010) and morphine reward and 
antinociception (Lutfy et al. 2003; Marquez et al. 2008; Rutten et al. 2011), it is not yet known what 
dose of buprenorphine would be required for NOP agonism to become relevant to drug-seeking 
behaviour in rats. 
 
In summary, it has been shown that a combination of 1.0 mg/kg naltrexone and 0.3 mg/kg 
buprenorphine, administered i.p. in Sprague Dawley rats, is non-rewarding and non-aversive, but 
results in high occupancy levels of both mu- and kappa-opioid receptors, and so acts as a 
functional mu/kappa-opioid receptor antagonist. It was then demonstrated that 0.3 mg/kg 
buprenorphine and 1.0 mg/kg naltrexone blocked drug-primed reinstatement to cocaine-seeking, 
and attenuated drug-primed morphine-seeking. These data add to the growing evidence that a 
buprenorphine/naltrexone combination may be effective in a polydrug abuse situation.  
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FIGURE LEGENDS 
Figure 1 Schematic of the time course of the conditioned place preference extinction and 
reinstatement method. Filled-in circles represent cocaine or morphine injections and empty circles 
represent saline injections (it can be seen that during conditioning the order of injections 
alternated daily). This schematic shows the reconditioning style of extinction, where each rat 
received 2 saline injections per day. The arrow indicates that buprenorphine/naltrexone treatment 
(or saline, in the control groups) was administered 10 minutes prior to the priming dose. 
 
Figure 2 The tail withdrawal assay and the CPP assay show how naltrexone blocks the mu-opioid 
receptor agonism of buprenorphine in a dose-dependent fashion. A Increase from baseline 
(seconds) in tail withdrawal assay at 60 minute time point (n = 5, 4, 7), mean + SEM. Baseline 
values were in the range 4 - 6 seconds; * indicates that first and third columns are significantly 
different from one another p<0.05. B % preference in CPP assay (n = 15, 7, 8, 16), mean + SEM; 
* indicates significantly different from baseline p<0.05. From left to right: 0.3 mg/kg buprenorphine, 
0.3 mg/kg buprenorphine and 0.3 mg/kg naltrexone, 0.3 mg/kg buprenorphine and 1.0 mg/kg 
naltrexone, and (conditioned place preference only) 0.3 mg/kg buprenorphine and 3.0 mg/kg 
naltrexone.  
 
Figure 3 The tail withdrawal assay shows antagonism of morphine by naltrexone, with and without 
buprenorphine. Data shows measurements taken 30 minutes after administration of 10 mg/kg 
morphine, and 60 minutes after administration of buprenorphine and/or naltrexone. From left to 
right, rats received 0 mg/kg buprenorphine (n = 5), 0.3 mg/kg buprenorphine and 1.0 mg/kg 
naltrexone (n = 4), and 1.0 mg/kg naltrexone (n = 7). Baseline values were in the range 4 - 5 
seconds. Mean + SEM; * indicates significantly different (p<0.05) vs. morphine alone group; ** 
indicates significantly different (p<0.05) vs. morphine alone group and vs. 0.3 mg/kg 
buprenorphine and 1.0 mg/kg naltrexone group. 
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Table 1 Number of rats used in the experiments, and excluded at each stage, and time taken to 
reach extinction. 
 
Figure 4 The CPP assay shows the effect of buprenorphine/naltrexone treatment on 
reinstatement to drug-seeking. % preference of rats (left to right in each panel: baseline, post-
conditioning, post-extinction and drug-primed reinstatement). Drug prime was 3 mg/kg cocaine or 
1.25 mg/kg morphine. A cocaine-conditioned control group (n = 12); B morphine-conditioned 
control group (n = 14). C cocaine-conditioned buprenorphine/naltrexone treated group (n = 9); D 
morphine-conditioned buprenorphine/naltrexone treated group (n = 8). Mean + SEM; * indicates 
significantly different from baseline p<0.05. Arrows indicate that buprenorphine/naltrexone 
treatment (0.3 mg/kg/1.0 mg/kg) was administered 10 minutes prior to the priming dose. 
 
Figure 5 Inhibition of electrically-evoked twitch in rat vas deferens by DAMGO. Effects of DAMGO are 
inhibited by buprenorphine (bup), A data from a single tissue; B pooled data from 4 tissues. Effects of 
DAMGO are inhibited by naltrexone (naltrex), C data from a single tissue; D pooled data from 5 
tissues; E Schild plot from data shown in D. Solid line: line of best-fit when slope constrained to 1, 
dashed line: 95% confidence limits. 
 
Table 2. Plasma and brain concentrations of buprenorphine and naltrexone and estimated receptor 
occupancies. Buprenorphine and naltrexone were administered simultaneously intraperitoneally. 
Plasma and brain samples were taken 30 minutes later and buprenorphine and naltrexone levels 
measured. The primary metabolites of buprenorphine and naltrexone (norbuprenorphine and 6β-
naltrexol) were also assayed but were below the limit of quantitation in plasma and brain samples. 
Using the plasma and brain concentrations, and empirically-determined KB values of both 
buprenorphine and naltrexone, receptor occupancy levels were determined. All data shows as mean ± 
S.E.M. 
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session
Baseline 
test
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Day 1            4            5             6            7       8            11          12          13           14        15           18
Conditioning
Test
Test
 
FIGURE 1 
 
 
 
 
 
 
 
 
 
 
 
 
 32
 
 
FIGURE 2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 33
 
 
FIGURE 3 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 34
 Cocaine  control cohort 
Morphine 
control cohort 
Cocaine  
treated cohort 
Morphine 
treated cohort 
At start 20 24 16 16 
Excluded for preference 0 2 2 1 
Excluded for insufficient 
conditioning 8 8 5 7 
Time taken to reach 
extinction 1 week 
1 week or 12 
days 1 week 1 week 
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FIGURE 4 
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FIGURE 5 
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 Buprenorphine 0.3 mg/kg Naltrexone 1.0 mg/kg 
 Observed concentration (nM) 
Predicted  
occupancy of mu 
receptor (%) 
Observed 
concentration (nM) 
Predicted 
 occupancy of mu 
receptor (%) 
Plasma 56 ± 4 38 285 ± 19 62  
Brain  83 ± 14 45 313 ± 19 55 
 
TABLE 2 
